Article

FDA advisory group likes Macugen but delays formal vote for now

New York-Members of the FDA's advisory committee reviewing pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration say they are "impressed" with the drug but declined to take a formal vote.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
Ocular pain in Tibetan Plateau residents: Key findings on dry eye disease during COVID-19
November 24th 2024

Ocular pain in Tibetan Plateau residents: Key findings on dry eye disease during COVID-19

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership
November 23rd 2024

Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept
November 23rd 2024

CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept

Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis
November 22nd 2024

Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis

© 2024 MJH Life Sciences

All rights reserved.